Broad HIV-1 inhibition in vitro by vaccine-elicited cd8(+) t cells in African adults.
dc.contributor.author | Mutua, G | |
dc.contributor.author | Farah, B | |
dc.contributor.author | Langat, R | |
dc.contributor.author | Indangasi, J | |
dc.contributor.author | Ogola, S | |
dc.contributor.author | Onsembe, B | |
dc.contributor.author | Kopycinski, JT | |
dc.contributor.author | Hayes, P | |
dc.contributor.author | Borthwick, NJ | |
dc.contributor.author | Ashraf, A | |
dc.contributor.author | Dally, L | |
dc.contributor.author | Barin, B | |
dc.contributor.author | Tillander, A | |
dc.contributor.author | Gilmour, J | |
dc.contributor.author | De Bont, J | |
dc.contributor.author | Crook, A | |
dc.contributor.author | Cox, JH | |
dc.contributor.author | Anzala, O | |
dc.contributor.author | Fast, PE | |
dc.contributor.author | Reilly, M | |
dc.contributor.author | Chinyenze, K | |
dc.contributor.author | Jaoko, W | |
dc.contributor.author | Hanke, T | |
dc.date.accessioned | 2017-05-09T06:23:11Z | |
dc.date.available | 2017-05-09T06:23:11Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Mol Ther Methods Clin Dev. 2016 Aug 31;3:16061. doi: 10.1038/mtm.2016.61. eCollection 2016. | en_US |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/27617268 | |
dc.identifier.uri | http://hdl.handle.net/11295/100827 | |
dc.description.abstract | We are developing a pan-clade HIV-1 T-cell vaccine HIVconsv, which could complement Env vaccines for prophylaxis and be a key to HIV cure. Our strategy focuses vaccine-elicited effector T-cells on functionally and structurally conserved regions (not full-length proteins and not only epitopes) of the HIV-1 proteome, which are common to most global variants and which, if mutated, cause a replicative fitness loss. Our first clinical trial in low risk HIV-1-negative adults in Oxford demonstrated the principle that naturally mostly subdominant epitopes, when taken out of the context of full-length proteins/virus and delivered by potent regimens involving combinations of simian adenovirus and poxvirus modified vaccinia virus Ankara, can induce robust CD8(+) T cells of broad specificities and functions capable of inhibiting in vitro HIV-1 replication. Here and for the first time, we tested this strategy in low risk HIV-1-negative adults in Africa. We showed that the vaccines were well tolerated and induced high frequencies of broadly HIVconsv-specific plurifunctional T cells, which inhibited in vitro viruses from four major clades A, B, C, and D. Because sub-Saharan Africa is globally the region most affected by HIV-1/AIDS, trial HIV-CORE 004 represents an important stage in the path toward efficacy evaluation of this highly rational and promising vaccine strategy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | University of Nairobi | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.title | Broad HIV-1 inhibition in vitro by vaccine-elicited cd8(+) t cells in African adults. | en_US |
dc.type | Article | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Faculty of Health Sciences (FHS) [10378]